Single Dose of Psilocybin Might Make Common Nerve Pain Drug Work Far Better

Chronic nerve pain affects millions of people worldwide, and for many who don’t respond to standard medications, treatment options are frustratingly limited. A new study adds an unexpected candidate to the conversation: a single dose of psilocybin, the active ingredient in so-called “magic mushrooms,” reduced chronic pain in mice on its own and dramatically boosted the effectiveness of a widely used pain drug called gabapentin, even weeks after the psilocybin was given.

Chronic nerve pain is notoriously difficult to treat. Conditions caused by nerve damage, from surgical injuries to diabetes, can leave people in relentless discomfort that current medications often fail to adequately control. Gabapentin is one of the most commonly prescribed drugs for this type of pain, yet somewhere between 30% and 50% of patients don’t get adequate relief from it alone, according to the study’s authors. A pre-print study published on Communications Biology raises the possibility that psilocybin could help remodel the brain’s pain-processing networks, potentially making existing medications work better for people who’ve run out of options. All of the work was done in mice and has not been tested in people.

What’s surprising isn’t that psilocybin helped with pain. It’s the timing. The pain-relief boost persisted long after the psilocybin had worn off. When gabapentin was given to mice weeks after a single psilocybin injection, at a point when the psilocybin itself was no longer providing any measurable pain relief, gabapentin still produced dramatic, long-lasting pain reduction. In mice that hadn’t received psilocybin, gabapentin’s effects were far weaker and shorter-lived.

How Researchers Tested Psilocybin for Nerve Pain

Researchers at the University of Reading, along with colleagues at University College London and Compass Pathfinder Ltd., a drug development subsidiary of Compass Pathways, used 157 mice for their experiments. Both male and female mice underwent a surgical procedure that damages nerve fibers in the leg, creating a long-lasting state of nerve pain that mirrors what humans experience after traumatic injury, surgery, or diabetes-related nerve damage.

Once the pain state was fully developed, typically around two weeks after surgery, the mice received a single injection of psilocybin, specifically COMP360, a synthetic formulation provided by Compass Pathfinder Ltd., or a saltwater placebo. To confirm the psilocybin was reaching the brain, researchers tracked a rapid, involuntary head-shaking behavior that mice display after receiving a psychedelic drug, widely considered the animal equivalent of a psychedelic experience.

Pain sensitivity was then measured over the following weeks using light brush strokes, cold surfaces, and calibrated pressure applied to the paw. Researchers also tracked body weight, stress indicators, and movement to confirm the drug wasn’t causing sedation or impairing normal activity. It didn’t.

Psilocybin Reduced Pain for Weeks, Then Made Gabapentin Work Dramatically Better

At the higher dose tested, 1 milligram per kilogram of body weight, psilocybin reduced pain sensitivity in both male and female mice. In males, that effect lasted up to 30 days after the single injection. In females, the effect lasted about one week, though the researchers noted that a more thorough look at how the drug affects females across different pain measures is still needed.

At a lower dose, pain relief was more modest but still lasted up to 28 days in male mice. When that lower dose was given once a week for three weeks, the pain-relieving effects were substantially amplified, reaching a much higher level of effectiveness than any single dose achieved.

One experiment tested whether giving psilocybin before nerve injury could prevent pain from developing in the first place. It couldn’t. Mice that received psilocybin 30 days before their surgery developed the same level of pain as those that didn’t get the drug. Psilocybin doesn’t appear to shield the nervous system from injury. Rather, it seems to work by reshaping pain pathways that have already gone wrong.

Why the Gabapentin Findings Could Matter for Chronic Pain Treatment

The most arresting part of the study involved gabapentin. In one experiment, researchers gave gabapentin to mice while psilocybin was still active in their system. The combination produced stronger and longer-lasting pain relief than gabapentin alone.

A second gabapentin experiment stood out even more. Researchers waited until day 55 after surgery, several weeks after psilocybin’s direct pain-relieving effects had faded and were no longer detectable. In mice that had previously received psilocybin, gabapentin produced a “dramatic and sustained” anti-nociceptive effect lasting from 2 to 96 hours. In mice that had only received the saltwater placebo, gabapentin’s response was markedly weaker and shorter.

According to the paper, this is “the first preclinical evidence that a psychedelic can serve as a pain-network primer for existing analgesics.” The authors suggest psilocybin may be doing something more fundamental than simply dulling pain signals. It may be causing lasting changes in the brain’s pain-processing networks in a way that makes them more responsive to conventional medications long afterward.

To understand how, researchers used a drug that blocks a specific brain receptor, called the 5-HT2A receptor, that psilocybin is known to activate. Blocking it reduced, though did not fully eliminate, psilocybin’s ability to relieve pain. That partial blockade points to other mechanisms also being at play. One candidate is a protein called BDNF, essentially a growth factor for brain cells. Psilocybin has been shown in other research to trigger BDNF release and spur the growth of new connections between brain cells, particularly in regions involved in decision-making and emotion. Whether BDNF-driven changes to brain circuits are what create a more receptive environment for gabapentin weeks later hasn’t been directly confirmed, but the authors identify it as a priority question for future research.

Most analgesics require chronic dosing and can lose effectiveness over time as patients build up tolerance, a pattern that has contributed to the prescription drug addiction crisis. A therapy that produces lasting changes from a single dose could sidestep that problem entirely. The authors describe the approach as “a paradigm shift in translatable chronic pain management: rather than developing entirely new drugs, a single dose of psilocybin could unlock the therapeutic potential of existing, well-characterised analgesics in treatment-resistant patients.” Whether the boosting effect extends to other pain medications, such as morphine, amitriptyline, or duloxetine, remains an open question the researchers say warrants immediate investigation.

All of this work was done in mice, which means there is still a long road to confirming these findings in people. But for patients who’ve cycled through medications without relief, the evidence that a single, carefully administered dose of a psychedelic compound might make their current prescriptions finally work is a result worth watching closely.

Disclaimer: This article is for informational purposes only and is not medical advice. The findings described are based on preclinical animal research conducted in mice and have not been tested in human patients. Psilocybin is not an approved treatment for chronic or neuropathic pain. Always consult a qualified healthcare professional before making any changes to your medications, supplements, or medical care.

Note: This article is based on an unedited, early-access version of the manuscript. The final published version may differ following additional editorial review.

---